Ensign Peak Advisors
KRON

Ensign Peak Advisors’s Kronos Bio KRON Stock Holding History

Ensign Peak Advisors’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,150
Closed -$20.2K – 1736
2023
Q4 		$20.2K Hold
16,150
– – ﹤0.01% 1735
2023
Q3 		$21K Hold
16,150
– – ﹤0.01% 1752
2023
Q2 		$27.8K Hold
16,150
– – ﹤0.01% 1757
2023
Q1 		$23.6K Sell
16,150
-325,653
-95% -$624K ﹤0.01% 1768
2022
Q4 		$554K Sell
341,803
-63,172
-16% -$145K ﹤0.01% 1591
2022
Q3 		$1.36M Hold
404,975
– – ﹤0.01% 930
2022
Q2 		$1.47M Sell
404,975
-35,714
-8% -$162K ﹤0.01% 940
2022
Q1 		$3.19M Sell
440,689
-19,462
-4% -$166K 0.01% 711
2021
Q4 		$6.25M Buy
460,151
+12,936
+3% +$202K 0.01% 600
2021
Q3 		$9.37M Sell
447,215
-33,954
-7% -$729K 0.02% 447
2021
Q2 		$11.5M Buy
481,169
+30,000
+7% +$759K 0.02% 404
2021
Q1 		$13.2M Buy
451,169
+237,278
+111% +$6.95M 0.03% 370
2020
Q4 		$6.39M Buy
+213,891
New +$6.71M 0.01% 531

Other funds holding KRON

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ensign Peak Advisors's KRON Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Kronos Bio (KRON) in Q1 2024, closing a stake of 16,150 shares — an estimated $20.2K sold.

Ensign Peak Advisors first reported a position in KRON in Q4 2020 and held it in 13 quarters. The position peaked at $13.2M in Q1 2021. 58 funds tracked by Wall St. Rank hold KRON as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Kronos Bio position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 16,150 Kronos Bio shares in Q1 2024, an estimated $20.2K.
  • Ensign Peak Advisors first reported a position in Kronos Bio in Q4 2020 and held it in 13 quarters.
  • Ensign Peak Advisors's Kronos Bio position peaked at $13.2M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.